American College of Surgeons ▲Pancreatic cancer

Measure Summaries

American College of Surgeons

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery have a risk-adjusted perioperative mortality of less than 5%?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery have endoscopic ultrasonography services available on site?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery have ERCP services available on site?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor the median operative time for resections?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor the stage-specific 2-year and 5-year survival rates for their patients who underwent pancreatectomy?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor their margin-negative resection rate?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor their median estimated blood loss?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor their pancreatic cancer resection risk-adjusted perioperative mortality?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery monitor their readmission-within-30-days rate?

• Pancreatic cancer: does the institution that performs pancreatic cancer surgery perform greater than or equal to 12 cases per year?

• Pancreatic cancer: does the institution that treats pancreatic cancer have radiation therapy and chemotherapy services available within their institution?

• Pancreatic cancer: does the institution that treats pancreatic cancer participate in clinical trials?

• Pancreatic cancer: percentage of patients not undergoing resection for whom chemotherapy or chemoradiation is considered or administered or a valid reason is documented for not receiving non-surgical therapy.

• Pancreatic cancer: percentage of patients to receive treatment for whom the time from diagnosis to surgery or first treatment is less than 2 months.

• Pancreatic cancer: percentage of patients to undergo resection for pancreatic cancer for whom, on the basis of CT or MRI scan, 1) no metastatic disease, 2) patent superior mesenteric vein and portal vein, and 3) a definable tissue plane between the tumor and regional arterial structures is preoperatively documented by the surgeon.

• Pancreatic cancer: percentage of patients undergoing cancer-directed resection for whom adjuvant chemotherapy with or without radiation is considered or administered, or a valid reason is documented for not receiving adjuvant therapy.

• Pancreatic cancer: percentage of patients undergoing cancer-directed resection for whom greater than or equal to 10 regional lymph nodes were resected and pathologically evaluated.

• Pancreatic cancer: percentage of patients undergoing cancer-directed resection in whom the margins are macroscopically clear.

• Pancreatic cancer: percentage of patients undergoing resection for whom the operative time is less than 10 hours.

• Pancreatic cancer: percentage of patients undergoing resection for whom the surgeon documents intraoperative findings in the operative note including the absence of 1) regional arterial involvement, 2) metastatic disease (liver, peritoneal, omental), and 3) distant adenopathy.

• Pancreatic cancer: percentage of patients with clinical stage I or II disease who undergo resection or have a valid reason documented for not undergoing resection.

• Pancreatic cancer: percentage of patients with clinical stage IV disease for whom cancer-directed surgery is not done.